Call for Abstract

International Conference on Myositis and Patient Safety, will be organized around the theme “Concepts in Myositis: Treatment and Diagnosis”

Myositis 2016 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Myositis 2016

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

 Myositis is an age related muscle disorder, which is most common among aged individuals and it may lead to severe disability due to its incurable nature. This muscle disorder is mainly characterized by inflammatory myopathy that slowly progresses and causes weakness of the limbs, least or no reflexes from deep tendons, mixing of neurogenic and myopathic changes in electromyography as well as dysphasia. Myositis is the most prevalent muscle disorder that mainly affects people over 50 years of age, but people may suffer from this disorder between 20 to 80 years of their ages. According to the estimates of, it was found that a population of 10.7 individuals per million in the U.S. are suffering from this disorder. The disease prevalence was least in the Netherlands in Europe with a population of 4.9 individuals per million. It was also found that people over 50 years of age in the least disease prevalent nations like Netherlands and Sweden have shown a prevalence of 16 individuals per million. Also, men are more prone to myositis with 4:1 to 3:1 ratio compared to the female population. Thus, high prevalence along with high geriatric population will contribute towards the growth of this market. Rising demand for advanced therapeutics and increasing number of drugs in the pipeline will contribute towards the growth of this market in future. 

  • Track 1-1Tension myositis syndrome
  • Track 1-2Viral myositis
  • Track 1-3Juvenile myositis
  • Track 1-4Lupus myositis
  • Track 1-5Eosinophilic myositis
  • Track 1-6Autoimmune myositis
  • Track 1-7Ocular myositis
  • Track 1-8Cervical myositis
  • Track 1-9Clostridial myositis
  • Track 1-10Interstitial myositis
  • Track 1-11Proliferative myositis

So far, most of the evidence suggests that polymyositis and dermatomyositis are autoimmune disorders, illnesses in which the immune system mistakenly attacks the body's own tissues. The muscles of people with inclusion body myositis contain an abnormal protein called amyloid, but the reason it forms is unknown. This amyloid protein is similar to the protein deposited in the brains of people with Alzheimer's disease, and some experts believe that the two diseases may develop the same way. In inclusion body myositis, the muscle also contains tiny structures that resemble viral particles (called inclusion bodies), although no viral infection has been consistently identified in association with this disease. In dermatomyositis, cancer is found in approximately 10% to 20% of cases. Sometimes, the muscle problem develops first. In other cases, the cancer is detected before the myositis.


  • Track 2-1Myositis ossificans
  • Track 2-2Inclusion Body Myositis
  • Track 2-3Myalgia myositis
  • Track 2-4Polymyositis
  • Track 2-5Dermatomyositis
  • Track 2-6Acute myositis
  • Track 2-7Infectious Myositis
  • Track 2-8Myopathies
Patient safety is a serious global public health issue. Estimates show that in developed countries as many as one in 10 patients is harmed while receiving hospital care.
Of every hundred 100 hospitalized patients at any given time, 7 in developed and 10 in developing countries will acquire health care-associated infections. Hundreds of millions of patients are affected by this worldwide each year.
  • Track 3-1Patient Safety Suggestions
  • Track 3-2Patient Safety
  • Track 3-3Patient Experience
  • Track 3-4Patient Critical Care
  • Track 3-5Patient Engagement

It is the disease featuring weakness and inflammation of muscles and muscle pain. The cause of much inflammatory myopathy is unknown i.e. idiopathic. The usual criteria for a diagnosis are weakness in muscles of the head, neck, trunk, upper arms or upper legs. They may be diagnosed by biopsy, MRI or electromyography. The biopsy findings of (i) muscle cell degeneration and regeneration and (ii) chronic inflammatory infiltrates in muscle cells. The goal of treatment is to improve the activities of daily living and muscle strength. The suppression of immune system activity i.e. immunosuppression is the treatment strategy. Every year between 2.18 and 7.7 people per million receive diagnosis. Around 3.2 children per million per year are diagnosed with an average age of onset of seven years. 

  • Track 4-1Musculoskeletal system
  • Track 4-2Symptoms and diagnosis
  • Track 4-3Congenital muscular dystrophy
  • Track 4-4Distal muscular dystrophy
  • Track 4-5Facioscapulohumeral muscular dystrophy
  • Track 4-6Limb-girdle muscular dystrophy
  • Track 4-7Chronic muscle inflammation
  • Track 4-8Muscle pain
  • Track 4-9Muscular myositis

The following symptoms are most common: Muscle pain and tenderness, often appearing first in the hips and shoulders, Muscle weakness, Difficulty with everyday tasks such as climbing stairs or rising from a chair, General fatigue (tiredness), Difficulty speaking or swallowing, Shortness of breath or coughing, Skin rash, Joint pain and swelling, Weight loss, Sensitivity to cold in the extremities (Raynaud's phenomenon), Fever, Atrophy (loss of muscle mass).

A diagnosis of myositis usually involves: A thorough patient history and physical exam, including hands-on tests of muscle strength. Blood tests for elevated levels of muscle enzymes and/or chemical inflammation markers. Electro-diagnostic testing, this uses needles and electrodes to measure muscle and motor nerve activity. Muscle or skin biopsy, in which a tissue sample is examined under a microscope. Magnetic resonance imaging (MRI) to pinpoint areas of muscle weakness. Other tests to rule out diseases with similar symptoms.

  • Track 5-1Clinical examination
  • Track 5-2Diagnostic testing
  • Track 5-3Conventional blood tests
  • Track 5-4Muscle and skin biopsy
  • Track 5-5Electro-diagnostic tests (EMI & EMG)
  • Track 5-6X-ray and cytopathology
  • Track 5-7Antibody testing
  • Track 5-8Pulmonary function tests

Immune system disorders cause abnormally low activity or over activity of the immune system. In cases of immune system over activity, the body attacks and damages its own tissues (autoimmune diseases). Immune deficiency diseases decrease the body's ability to fight invaders, causing vulnerability to infections.

In response to an unknown trigger, the immune system may begin producing antibodies that instead of fighting infections, attack the body's own tissues. Treatment for autoimmune diseases generally focuses on reducing immune system activity.

  • Track 6-1Chronic immune diseases
  • Track 6-2Acute immune diseases
  • Track 6-3Rheumatoid arthritis
  • Track 6-4Scleroderma
  • Track 6-5Autoimmune disease
  • Track 6-6Cancer and myositis

The key factors responsible for the dominance in myositis market can be the presence of high geriatric population along with high demand for advanced therapeutics for effective treatment of the disorder in many regions. In some cases there is no complete cure for myositis so researchers are working to develop universal treatment that can be more effective. Studies are also being conducted to find new drugs and therapeutics

The global market revenue for advanced orthopaedics grew from $35.3 billion in 2013 to $36.4 billion in 2014. The global orthopaedic device market was valued at $29.2 billion in 2012 and is expected to reach $41.2 billion by 2019. The market is expected to grow at a compound annual growth rate of 4.9 % over the next five years, according to the Transparency Market Research report. The global rheumatology therapeutics market was estimated to be worth $17.1 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 9.4% from 2005, and is forecast to grow at a CAGR of 4.8% to $23.8 billion by 2018. Companies that produce myositis drugs: Gradalis, Inc., New Zealand Pharmaceuticals Ltd., Nobelpharma Co. Ltd., Novartis AG.,  Drugs u Bayer Healthcare, Bloomberg Medical Group, Bone SA, BSN Medical (PTY) Ltd South Africa, DJO Global, Elite Surgical, FLUOROVIZION, KARL STORZ Endoscopy (South Africa) (PTY) LTD, MEDISMEDICAL, Ortho-Xact, Professional Orthopaedics (PTY) LTD, SportsMed Ortho (Pty) Ltd,  Smith & Nephew, STRATMED, SURGITECH,  WERKOMED.

  • Track 7-1Drugs and myositis treatment
  • Track 7-2Companies that produce myositis drugs
  • Track 7-3Case Studies
  • Track 7-4Clinical trials in myositis
  • Track 7-5Diagnostic machines and equipments
  • Track 7-6The global market revenue for advanced myositis treatment
  • Track 7-7Strategies to contain outbreaks on local and global scenarios

Many biotech companies are founded by scientists. But there is certainly a path, somewhat less trodden but nonetheless viable, for the inspired entrepreneur who may not be a brilliant researcher.

Each year, over a million companies are started in the US with about 5–10% (57,793 in 1998) of them classified as high technology companies1. Many nascent entrepreneurs exist around us, and thinking about starting a new venture is not an uncommon activity—in fact at any given point in time, over 4% of the working age population might be thinking of an idea for a new venture2. Not surprisingly, turning ideas into business ventures is tricky: only about 10% of budding entrepreneurs have a new firm in place within 12–18 months3; the other 90% either fail to define a sound business model that can drive their business idea forward to a new venture or realize their idea was flawed.

A key ingredient in successful entrepreneurship is self-knowledge. If entrepreneurs know their limitations and strengths, they may be able to avoid some common pitfalls in starting up a biotech company.


  • Track 8-1Future myositis research development
  • Track 8-2Pharma market involvement in myositis
  • Track 8-3B2B discussions
  • Track 8-4Product workshops - Myositis diagnosis and analysis

Researchers are making some progress in understanding what happens in myositis and what goes wrong with the immune system. Currently they believe that the muscle fibres in some people with myositis are damaged by a group of cells called lymphocytes which make up part of the immune system. Researchers also are studying the possibility that certain autoantibodies may travel through the blood and cause damage to the muscle. Other researchers are studying how many different forms of myositis exist and how they are different from one another in their cause and treatment. Musculoskeletal system disorder is another of its kind. Other disorders caused by it also include arthritis. They not only cause internal damages but also cause different skin infections. As scientists get closer to understanding the process leading to muscle damage in the different forms of myositis they can hope to find new ways of stopping the harmful actions. With the scientific progress that has been made in recent years people with myositis have reason to share that hope. Research holds the key to better ways to prevent diagnose and control myositis.

  • Track 9-1Myositis ossificans treatment
  • Track 9-2Inclusion body myositis treatment
  • Track 9-3Viral myositis treatment
  • Track 9-4Tension myositis syndrome treatment
  • Track 9-5Advances in myositis diagnosis


Rheumatologists and orthopaedic doctors treating these conditions work to minimize pain and discomfort in the joints. Treatment focuses on improving quality of life and getting patients back to the activities they enjoy. While non-operative solutions, such as physical therapy, steroid injections into the joint, and lifestyle modification, can be effective in treating painful musculoskeletal conditions, surgery is sometimes necessary to alleviate rheumatic symptoms. Prior to beginning a treatment for a condition such as osteoarthritis or rheumatoid arthritis, it is best to speak with an orthopaedic doctor or rheumatologist to ensure the best treatment path possible. When a rheumatologist feels that treatment will no longer alleviate the pain and disability


  • Track 10-1Fracture Management
  • Track 10-2Connective tissue diseases
  • Track 10-3Rheumatic diseases
  • Track 10-4Musculoskeletal trauma
  • Track 10-5Sports injuries
  • Track 10-6Arthritis and autoimmune diseases
  • Track 10-7Congenital disorders
  • Track 10-8Infections and tumors

Therapies for accelerating muscle regeneration, primarily through inhibition of

myostatin, have shown promise in the laboratory and are now entering clinical trials.

Recent studies have implicated autophagy, a key cellular process involved in clearance of ubiquitinated aggregates, in the pathogenesis of familial and sporadic inclusion body myositis (sIBM). IBM has joined a growing list of diseases known as TDP-43 proteinopathies, in which this protein becomes mislocalized to the cytoplasm; however, it is unclear whether these protein aggregates or others are pathogenic in this disease. New discoveries of biomarkers in sIBM and new insights into the pathogenesis of familial IBM are opening novel therapeutic pathways for these disorders. In particular, drugs that stimulate autophagy, already in development for cancer and neurodegenerative diseases, are candidates for clinical trials. These disease-specific therapies combined with novel therapies to accelerate muscle regeneration hold promise for future therapy for this devastating disease.

  • Track 11-1Natural remedies and herbs
  • Track 11-2Complimentary treatment methods
  • Track 11-3Chair yoga for myositis
  • Track 11-4Natural therapy for polymyositis
  • Track 11-5Chronic muscle inflammationHealing and wellness myositis treatment
  • Track 11-6Spiritual myositis treatment
  • Track 11-7Traditional and alternative medicine
  • Track 11-8Myositis nutrition management

Pain is a global phenomenon in which it has been estimated that 20% of adults and 8% of children suffer from at any one time of whom 10% suffer chronic pain. Pain is the leading reason for primary care consultations (80%) and musculoskeletal pain is the commonest reason for work absenteeism. Pain is complex and there are aspects that require better recognition and understanding in order to improve its treatment and management.
Pain has been defined as ‘An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’. Pain is generally relieved soon after it is perceived. However, for some the sensation persists long after the normal physiological processes of healing have occurred, leading to persistent daily pain which affect a person’s ability to function and to engage socially and/or emotionally and impacts on their quality of life. Pain is not always linked to pathology and as professionals we may not be able to identify its cause. Never the less in such cases it is important to acknowledge that pain reported by the sufferer will have physiological and psychological aspects in addition
to factors that contribute to persistence. The management of pain can involve pharmacological, surgical or non-pharmacological procedures. Successful interventions are dependent on identifying the causes of the pain and recognising
its multi-systemic nature. To address the multi-systemic aspects requires an inter-professional holistic approach involving the expertise of different medical specialists in collaboration with the pain sufferer. Pain sufferers have also requested education about their pain experience but this can only happen if professionals are able to
adequately communicate their understanding of pain.

  • Track 12-1Occupational therapy
  • Track 12-2Pediatric myositis physiotherapy
  • Track 12-3Sports myositis phyiotherapy
  • Track 12-4Myositis physiotherapeutic treatment
  • Track 12-5Physical medicine and myositis education programs
  • Track 12-6Myositis rehabilitation healthcare measures
  • Track 12-7Yoga and exercise
  • Track 12-8Trauma rehabilitation

People with myositis may have significant functional limitations and disability despite appropriate pharmacologic treatment to reduce inflammatory damage to their muscles. The impairments associated with myositis often result in a loss of independent ambulation, difficulty rising from a chair, an inability to negotiate stairs, and diminished health-related quality of life. Therefore, meaningful outcomes measures and effective therapeutic exercise remain important in the medical management of the disease.




  • Track 13-1Nursing practise and education
  • Track 13-2Clinical and post rehabilitation nursing
  • Track 13-3Nursing interventions in myositis
  • Track 13-4Myositis nursing care plan
  • Track 13-5Myositis prognosis
  • Track 14-1Viral myositis in children
  • Track 14-2Post-viral myositis in children
  • Track 14-3Myalgia myositis in children
  • Track 14-4Autoimmune myositis in children
  • Track 14-5Acute myositis in children
  • Track 14-6Myositis ossificians in children
  • Track 14-7Pain and Inflammation